Login to Your Account

Prosensa Closes $30M C Round for Exon-Skipping Drug Pipeline

By Cormac Sheridan
Staff Writer

Wednesday, February 1, 2012

Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round last week to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription